Sameer S Kadri1, Samuel F Hohmann2, E John Orav3, Stephanie L Bonne4, Matthew A Moffa5, Joseph G Timpone5, Jeffrey R Strich6, Tara Palmore7, Kenneth B Christopher8, Christy Varughese9, David C Hooper10, Robert L Danner11. 1. Critical Care Medicine Department Division of Infectious Diseases. 2. University HealthSystem Consortium Department of Health Systems Management, Rush University, Chicago, Illinois. 3. Department of Medicine, Harvard Medical School. 4. Department of General Surgery, Barnes Jewish Hospital, St. Louis, Missouri. 5. Division of Infectious Diseases and Travel Medicine. 6. Department of Medicine, Georgetown University Hospital, Washington, District of Columbia. 7. Hospital Epidemiology Service, Clinical Center, National Institutes of Health, Bethesda, Maryland. 8. Renal Division, Brigham and Women's Hospital, Boston, Massachusetts. 9. Department of Pharmacy, Massachusetts General Hospital. 10. Division of Infectious Diseases. 11. Critical Care Medicine Department.
Abstract
BACKGROUND: Existing surveillance mechanisms may underestimate the incidence of carbapenem-resistant gram-negative infections (CRGNIs). Although carbapenem resistance increases the risk of death, the trend in mortality over time is unknown. METHODS: A retrospective cohort study was conducted at 40 academic medical centers using a discharge database to identify adult hospital admissions without cystic fibrosis in 2006-2012 and received intravenous colistin for >3 consecutive days or died during therapy (termed colistin cases). The primary outcomes were the number of colistin cases per 100,000 admissions per year and change in the hospital mortality rate over time compared with the rate of discharges to home. Secondary outcomes included median overall and intensive care unit lengths of stay. RESULTS: From 2006 to 2012, a total of 5011 unique patients were identified as colistin cases. The number per 100,000 admissions per year increased from 35.56 to 92.98 during the 7-year study (P < .001). The odds of in-hospital death among colistin cases (compared with discharge to home) decreased by a mean of 5.2%/y (P = .04), whereas discharge to an institution (P = .24) or hospice (P = .89) remained steady over time. The median overall and intensive care unit lengths of stay decreased by 7.5 and 6 days, respectively (P < .001). In a 4-hospital chart review, 81.6% of colistin cases were found to have culture-positive CRGNIs. Conversely, 53% of extensively drug-resistant bloodstream CRGNIs at 2 of these hospitals met colistin case criteria. CONCLUSIONS: Colistin cases represent a severely ill population with a high probability of having culture-confirmed CRGNIs. Colistin tracking is a novel strategy for monitoring the incidence and mortality of CRGNIs, particularly those caused by extensively drug-resistant bacteria. Although the incidence of colistin cases nearly tripled within 7 years, more of these patients are surviving hospitalization and going home. Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2014. This work is written by (a) US Government employee(s) and is in the public domain in the US.
BACKGROUND: Existing surveillance mechanisms may underestimate the incidence of carbapenem-resistant gram-negative infections (CRGNIs). Although carbapenem resistance increases the risk of death, the trend in mortality over time is unknown. METHODS: A retrospective cohort study was conducted at 40 academic medical centers using a discharge database to identify adult hospital admissions without cystic fibrosis in 2006-2012 and received intravenous colistin for >3 consecutive days or died during therapy (termed colistin cases). The primary outcomes were the number of colistin cases per 100,000 admissions per year and change in the hospital mortality rate over time compared with the rate of discharges to home. Secondary outcomes included median overall and intensive care unit lengths of stay. RESULTS: From 2006 to 2012, a total of 5011 unique patients were identified as colistin cases. The number per 100,000 admissions per year increased from 35.56 to 92.98 during the 7-year study (P < .001). The odds of in-hospital death among colistin cases (compared with discharge to home) decreased by a mean of 5.2%/y (P = .04), whereas discharge to an institution (P = .24) or hospice (P = .89) remained steady over time. The median overall and intensive care unit lengths of stay decreased by 7.5 and 6 days, respectively (P < .001). In a 4-hospital chart review, 81.6% of colistin cases were found to have culture-positive CRGNIs. Conversely, 53% of extensively drug-resistant bloodstream CRGNIs at 2 of these hospitals met colistin case criteria. CONCLUSIONS: Colistin cases represent a severely ill population with a high probability of having culture-confirmed CRGNIs. Colistin tracking is a novel strategy for monitoring the incidence and mortality of CRGNIs, particularly those caused by extensively drug-resistant bacteria. Although the incidence of colistin cases nearly tripled within 7 years, more of these patients are surviving hospitalization and going home. Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2014. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Entities:
Keywords:
carbapenem resistance; colistin; extensively drug resistant; gram-negative infection; surveillance
Authors: Diana F Florescu; Fang Qiu; Megan A McCartan; Cezarina Mindru; Paul D Fey; A C Kalil Journal: Clin Infect Dis Date: 2012-03-01 Impact factor: 9.079
Authors: Elizabeth K Stevenson; Amanda R Rubenstein; Gregory T Radin; Renda Soylemez Wiener; Allan J Walkey Journal: Crit Care Med Date: 2014-03 Impact factor: 7.598
Authors: John S Esterly; Milena Griffith; Chao Qi; Michael Malczynski; Michael J Postelnick; Marc H Scheetz Journal: Antimicrob Agents Chemother Date: 2011-08-08 Impact factor: 5.191
Authors: A Batirel; I I Balkan; O Karabay; C Agalar; S Akalin; O Alici; E Alp; F A Altay; N Altin; F Arslan; T Aslan; N Bekiroglu; S Cesur; A D Celik; M Dogan; B Durdu; F Duygu; A Engin; D O Engin; I Gonen; E Guclu; T Guven; C A Hatipoglu; S Hosoglu; M K Karahocagil; A U Kilic; B Ormen; D Ozdemir; S Ozer; N Oztoprak; N Sezak; V Turhan; N Turker; H Yilmaz Journal: Eur J Clin Microbiol Infect Dis Date: 2014-02-15 Impact factor: 3.267
Authors: Sameer S Kadri; Jeffrey R Strich; Bruce J Swihart; Samuel Hohmann; John P Dekker; Tara Palmore; Stephanie Bonne; Bradley Freeman; Jillian Raybould; Nirav G Shah; Devang Patel; Jennifer Husson; Mitchell D Jacobs; Lan Duong; Dean Follmann; David C Hooper; Joseph Timpone; Robert L Danner Journal: Am J Infect Control Date: 2019-02-27 Impact factor: 2.918
Authors: Sameer S Kadri; Chanu Rhee; Jeffrey R Strich; Megan K Morales; Samuel Hohmann; Jonathan Menchaca; Anthony F Suffredini; Robert L Danner; Michael Klompas Journal: Chest Date: 2016-07-22 Impact factor: 9.410
Authors: Sameer S Kadri; Andrew C Miller; Samuel Hohmann; Stephanie Bonne; Carrie Nielsen; Carmen Wells; Courtney Gruver; Sadeq A Quraishi; Junfeng Sun; Rongman Cai; Peter E Morris; Bradley D Freeman; James H Holmes; Bruce A Cairns; Anthony F Suffredini Journal: Chest Date: 2016-06-15 Impact factor: 9.410
Authors: Jeffrey R Strich; Emily Ricotta; Sarah Warner; Yi Ling Lai; Cumhur Y Demirkale; Samuel F Hohmann; Chanu Rhee; Michael Klompas; Tara Palmore; John H Powers; John P Dekker; Jennifer Adjemian; Roland Matsouaka; Christopher W Woods; Robert L Danner; Sameer S Kadri Journal: Clin Infect Dis Date: 2021-02-16 Impact factor: 9.079
Authors: Sameer S Kadri; Bruce J Swihart; Stephanie L Bonne; Samuel F Hohmann; Laura V Hennessy; Peter Louras; Heather L Evans; Chanu Rhee; Anthony F Suffredini; David C Hooper; Dean A Follmann; Eileen M Bulger; Robert L Danner Journal: Clin Infect Dis Date: 2017-04-01 Impact factor: 9.079
Authors: Honghui Wang; Yong Chen; Jeffrey R Strich; Steven K Drake; Jung-Ho Youn; Avi Z Rosenberg; Marjan Gucek; Patrick T McGann; Anthony F Suffredini; John P Dekker Journal: Clin Proteomics Date: 2019-02-26 Impact factor: 3.988
Authors: Chanu Rhee; Sameer S Kadri; John P Dekker; Robert L Danner; Huai-Chun Chen; David Fram; Fang Zhang; Rui Wang; Michael Klompas Journal: JAMA Netw Open Date: 2020-04-01